Erectile Dysfunction Treatment Guidelines
Introduction to Treatment Options
- Oral phosphodiesterase type 5 (PDE5) inhibitors should be offered as first-line therapy for erectile dysfunction unless contraindicated, followed by more invasive options in a stepwise approach based on efficacy and invasiveness 1, 2
First-Line Treatment
- These medications should be titrated to provide optimal efficacy 2
- Proper instructions should be provided to maximize benefit/efficacy 2
Second-Line Treatments
- Intracavernous injection therapy using vasodilator drugs such as alprostadil, papaverine, or phentolamine is effective for patients who fail to respond to oral agents 1
- Intra-urethral alprostadil suppositories are another option 1
- Non-invasive mechanical option for patients who cannot use or do not respond to pharmacological treatments 1
Third-Line Treatment
- Penile prosthesis implantation is reserved for patients who fail less invasive treatments 1
Adjunctive Treatments
- Optimal management of comorbid conditions like diabetes, hypertension, and heart disease may help prevent or improve ED 1
- Psychosexual therapy is useful in combination with both medical and surgical treatments 1
- Psychosexual therapy is particularly beneficial for patients with predominantly psychogenic ED 2
- Helps improve communication about sexual concerns and reduce anxiety 2
- Testosterone therapy should be considered in men with confirmed testosterone deficiency 2
Special Considerations
- ED is a risk marker for cardiovascular disease 2
- Patients with ED should be evaluated for cardiovascular risk factors 2
- The Princeton Consensus Panel guidelines recommend assigning patients to risk categories (low, intermediate, high) to guide ED treatment in the context of cardiovascular health 1
- High-risk patients should not receive treatment for sexual dysfunction until their cardiac condition has stabilized 1
- Failure to recognize ED as a potential marker of underlying cardiovascular disease 2
- Not discussing treatment options and their risks/benefits with both the patient and partner when possible 1
- Not titrating PDE5 inhibitor doses to achieve optimal efficacy 2
- Not considering psychosexual factors that may contribute to or exacerbate ED 2
- Treatment should be applied in a stepwise fashion with increasing invasiveness and risk balanced against the likelihood of efficacy, always considering the patient's cardiovascular status and preferences 1